Interpace Biosciences Overview

  • Year Founded
  • 1988

Year Founded

  • Status
  • Public

  • Employees
  • 102

Employees

  • Stock Symbol
  • IDXG

Stock Symbol

  • Investments
  • 9

  • Share Price
  • $4.40
  • (As of Friday Closing)

Interpace Biosciences General Information

Description

Interpace Biosciences Inc provides esoteric molecular diagnostic testing and pathology services to aid physicians in evaluating cancer risk in patients with indeterminate biopsies and a perceived high risk of cancer based on clinical features. The company develops and commercializes genomic tests and related first-line assays that can personalize medicine and help improve patient diagnosis and management. Its clinical customers mainly consist of physicians, hospitals, cancer centers, commercial laboratories, pathology groups, and clinics. The various diagnostic tests offered by the company include ThyGeNEXT and ThyraMIRv2 for the detection of thyroid cancer.

Contact Information

Formerly Known As
PDI, Interspace Diagnostics, Interpace Diagnostics Group, Inc., Professional Detailing Inc
Ownership Status
Publicly Held
Financing Status
Private Debt Financed
Corporate Office
  • 2001 Route 46 Waterview Plaza
  • Suite 310
  • Parsippany, NJ 07054
  • United States
+1 (855)
Primary Industry
Laboratory Services (Healthcare)
Stock Exchange
OTCM
Vertical(s)
Corporate Office
  • 2001 Route 46 Waterview Plaza
  • Suite 310
  • Parsippany, NJ 07054
  • United States
+1 (855)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Interpace Biosciences Stock Performance

As of 20-Nov-2026, Interpace Biosciences’s stock price is $4.40. Its current market cap is $26M with 5.9M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$4.40 $4.60 $4.15 - $12.00 $26M 5.9M 2.88K $25.46

Interpace Biosciences Financials Summary

As of 30-Sep-2026, Interpace Biosciences has a trailing 12-month revenue of $37.8M.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 36,000 6,285 63,487 59,707
Revenue 37,761 38,728 46,926 40,036
EBITDA 1,562 4,763 8,357 4,890
Net Income 21,926 24,575 6,702 1,954
Total Assets 37,468 33,838 14,792 13,116
Total Debt 864 1,183 5,856 11,192
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Interpace Biosciences Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Interpace Biosciences‘s full profile, request access.

Request a free trial

Interpace Biosciences Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Interpace Biosciences Inc provides esoteric molecular diagnostic testing and pathology services to aid physicians in eva
Laboratory Services (Healthcare)
Parsippany, NJ
102 As of 2026

Louisville, CO
 

Fort Myers, FL
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Interpace Biosciences Competitors (26)

One of Interpace Biosciences’s 26 competitors is Biodesix, a Formerly VC-backed company based in Louisville, CO.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Biodesix Formerly VC-backed Louisville, CO
NeoGenomics Corporation Fort Myers, FL
Agendia Venture Capital-Backed Irvine, CA
BioReference Health Corporate Backed or Acquired Elmwood Park, NJ
PathGroup Private Equity-Backed Brentwood, TN
You’re viewing 5 of 26 competitors. Get the full list »

Interpace Biosciences Patents

Interpace Biosciences Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20180327856-A1 Diagnostic mirnas for differential diagnosis of incidental pancreatic cystic lesions Inactive 04-Oct-2012
EP-2771487-A1 Mirnas as diagnostic biomarkers to distinguish benign from malignant thyroid tumors Inactive 27-Oct-2011
US-20190017122-A1 Mirnas as diagnostic biomarkers to distinguish benign from malignant thyroid tumors Inactive 27-Oct-2011
US-10655184-B2 Methods and compositions involving mir-135b for distinguishing pancreatic cancer from benign pancreatic disease Active 13-Sep-2011
US-20180066316-A1 Methods and compositions involving mir-135b for distinguishing pancreatic cancer from benign pancreatic disease Active 13-Sep-2011 C12Q1/6886
To view Interpace Biosciences’s complete patent history, request access »

Interpace Biosciences Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Interpace Biosciences Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Interpace Biosciences‘s full profile, request access.

Request a free trial

Interpace Biosciences Investments & Acquisitions (9)

Interpace Biosciences’s most recent deal was a Merger/Acquisition with Cancer Genetics (Biopharma Services) for . The deal was made on 15-Jul-2019.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Cancer Genetics (Biopharma Services) 15-Jul-2019 Merger/Acquisition Laboratory Services (Healthcare)
Rosetta Genomics (Philadelphia Laboratory Equipments) 15-Aug-2018 Corporate Asset Purchase Buildings and Property
RedPath Integrated Pathology 03-Nov-2014 Merger/Acquisition Laboratory Services (Healthcare)
JS Genetics 21-Aug-2014 Merger/Acquisition Laboratory Services (Healthcare)
Asuragen (MiRInform Thyroid and Pancreas Cancer Test Assets) 13-Aug-2014 Corporate Asset Purchase Buildings and Property
You’re viewing 5 of 9 investments and acquisitions. Get the full list »

Interpace Biosciences ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Healthcare

Industry

Rank

Percentile

Medical Services

Subindustry

Rank

Percentile

To view Interpace Biosciences’s complete esg history, request access »

Interpace Biosciences Exits (3)

Interpace Biosciences’s most recent exit was on 04-Nov-2010 from Group DCA. The exit was categorized as .

Company Name Exit Date Exit Type Exit Size Status Buyers
Group DCA 04-Nov-2010 Completed
Xylos Corp 10-Feb-2006 Completed
  • 9 buyers
Pharmakon (Biological Product) 31-Aug-2004 Merger/Acquisition Completed
To view Interpace Biosciences’s complete exits history, request access »

Interpace Biosciences FAQs

  • When was Interpace Biosciences founded?

    Interpace Biosciences was founded in 1988.

  • Where is Interpace Biosciences headquartered?

    Interpace Biosciences is headquartered in Parsippany, NJ.

  • What is the size of Interpace Biosciences?

    Interpace Biosciences has 102 total employees.

  • What industry is Interpace Biosciences in?

    Interpace Biosciences’s primary industry is Laboratory Services (Healthcare).

  • Is Interpace Biosciences a private or public company?

    Interpace Biosciences is a Public company.

  • What is Interpace Biosciences’s stock symbol?

    The ticker symbol for Interpace Biosciences is IDXG.

  • What is the current stock price of Interpace Biosciences?

    As of 20-Nov-2026 the stock price of Interpace Biosciences is $4.40.

  • What is the current market cap of Interpace Biosciences?

    The current market capitalization of Interpace Biosciences is $26M.

  • What is Interpace Biosciences’s current revenue?

    The trailing twelve month revenue for Interpace Biosciences is $37.8M.

  • Who are Interpace Biosciences’s competitors?

    Biodesix, NeoGenomics, Agendia, BioReference Health, and PathGroup are some of the 26 competitors of Interpace Biosciences.

  • What is Interpace Biosciences’s annual earnings per share (EPS)?

    Interpace Biosciences’s EPS for 12 months was $25.46.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process